Publications

Show Filters

Searches all publications.

Search Fulltext

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-11-19
    E.g., 2018-11-19

Articles

Pages

3412 items
12:00 AM, Jun 06, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg6/3 clsCymaBay Therapeutics Inc. (NASDAQ:CBAY)H.C. WainwrightEd ArceDowngradeNeutral (from buy)-19%$1.97 Arce also lowered his target to $2.25 from $6 after CymaBay reported mixed results from a Phase II trial...
12:00 AM, May 30, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg5/27 clsAlkermes plc (NASDAQ:ALKS)Evercore ISIUmer RaffatNewBuy7%$46.13 Raffat initiated coverage with a $59 target. He models a 65% probability of positive data from the Phase III FORWARD-5 trial of...
12:00 AM, May 23, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg5/20 clsArbutus Biopharma Corp. (NASDAQ:ABUS)Chardan CapitalMadhu KumarNewSell-6%$4.08 Kumar initiated coverage with a $3.25 target, saying competition to Arbutus' lead asset, ARB-1467, raises hurdles ahead of 2H16 catalysts. He...
12:00 AM, May 16, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg5/13 clsContraFect Corp. (NASDAQ:CFRX)Roth Capital PartnersJoseph PantginisDowngradeNeutral (from buy)-32%$2.20 Pantginis also lowered his target to $3.30 from $14. He predicts it will be 1.5-2 years before Phase II...
12:00 AM, May 09, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg5/6 clsAcadia Pharmaceuticals Inc. (NASDAQ:ACAD)Leerink PartnersPaul MatteisDowngradeMarket perform (from outperform)-14%$27.65 Matteis also lowered his target to $35 from $40. He remains "confident in the value proposition of pimavanserin"...
12:00 AM, May 02, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg4/29 clsDynavax Technologies Corp. (NASDAQ:DVAX)RBC Capital MarketsSimos SimeonidisDowngradeSector performer (from outperform)-26%$16.41 Simeonidis also lowered his target to $17 from $48 on continued concerns about Heplisav-B's safety. FDA extended...
12:00 AM, Apr 25, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg4/22 clsChiasma Inc. (NASDAQ:CHMA)CowenRitu BaralDowngradeMarket perform (from outperform)-62%$3.83 William BlairTim LugoDowngradeMarket perform (from outperform)Baral also removed her $32 target after FDA issued a complete response letter to an...
12:00 AM, Apr 11, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg4/8 clsBind Therapeutics Inc. (NASDAQ:BIND)CowenEric SchmidtDowngradeMarket perform (from outperform)-30%$1.57 Michael KingDowngradeMarket perform (from market outperform)Schmidt downgraded after Bind reported mixed results from two Phase II trials of BIND-014....
12:00 AM, Apr 04, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg1/1 clsAchaogen Inc. (NASDAQ:AKAO)CowenRitu BaralDowngradeMarket perform (from outperform)-9%$2.71 Baral downgraded on near-term cash flow concerns. She said Achaogen is counting on the extension of contracts with HHS's Biomedical...
12:00 AM, Mar 28, 2016  |  BioCentury | Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changesCompanyBankAnalystCoverageOpinionWk chg3/24 clsIronwood Pharmaceuticals Inc. (NASDAQ:IRWD)Goldman SachsJami RubinNewNeutral1%$10.39 Rubin initiated coverage with a $14 target. She said Ironwood is a commercial biopharma on the cusp of turning profitable in...

Pages